Guangzhou Virotech Pharmaceutical Co., Ltd.

This early-stage trial is testing a new injection called VRT106 in patients whose glioblastoma, a fast-growing brain cancer, has returned or gotten worse. The main goals are to find a safe dose and see if the treatment shows any early signs of helping. The study will enroll 42 ad…

This is an early-stage study testing the safety of a modified virus called VRT106, which is designed to infect and kill cancer cells. The virus is injected directly into tumors of patients with advanced solid cancers who have no other effective treatment options. Researchers will…